With a growing portfolio of FDA-regulated eye-care products already on the market, Thea Pharma US has now closed an $8.0M seed funding round. The Lexington, Massachusetts-based company, established in 2019 as the U.S. subsidiary of Théa, aims to expand its reach in ophthalmic treatment.
Thea Pharma US offers a range of seven leading eye-care products, including Zioptan®, AcellFX™, Cosopt®, and iVIZIA dry-eye drops, alongside its newest offering, IYUZEH™. The capital infusion marks a significant step for the young subsidiary as it focuses its expertise on delivering uncompromising care within the U.S. market.
